Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 6, Issue 240, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3007646
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) [RO1-158800]
- UW Institute for Clinical and Translational Research pilot grant [9U54TR000021]
- Cellectar Biosciences Inc.
- NIH [T32CA009206]
- UW MSTP (Medical Scientist Training Program) [T32GM008692]
- UW Carbone Cancer Center
- Wisconsin Partnership Program core grant support of the Center for Stem Cell and Regenerative Medicine
- University of Wisconsin (Graduate School and Department of Neurological Surgery)
- HEAD-RUSH Brain Tumor Research Professorship
- Roger Loff Memorial Fund for GBM Research
- UW Carbone Cancer Center NCI Support grant [P30 CA014520]
- University of Wisconsin (Graduate School, Departments of Radiology, Medical Physics, Human Oncology, and Neurological Surgery, Wisconsin Alumni Research Foundation, and Wisconsin Institutes of Discovery)
Ask authors/readers for more resources
Many solid tumors contain an overabundance of phospholipid ethers relative to normal cells. Capitalizing on this difference, we created cancer-targeted alkylphosphocholine (APC) analogs through structure-activity analyses. Depending on the iodine isotope used, radioiodinated APC analog CLR1404 was used as either a positron emission tomography (PET) imaging (I-124) or molecular radiotherapeutic (I-131) agent. CLR1404 analogs displayed prolonged tumor-selective retention in 55 in vivo rodent and human cancer and cancer stem cell models. I-131-CLR1404 also displayed efficacy (tumor growth suppression and survival extension) in a wide range of human tumor xenograft models. Human PET/CT (computed tomography) and SPECT (single-photon emission computed tomography)/CT imaging in advanced-cancer patients with I-124-CLR1404 or I-131-CLR1404, respectively, demonstrated selective uptake and prolonged retention in both primary and metastatic malignant tumors. Combined application of these chemically identical APC-based radioisosteres will enable personalized dual modality cancer therapy of using molecular I-124-CLR1404 tumor imaging for planning I-131-CLR1404 therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available